AGI: Gaming Equipment Specialist - Horse Racing's Hidden Gem
Deep value opportunity trading at A$1.01 vs A$3.13 fair value. HHR network dominance with 10,496 units, pending Novomatic acquisition catalyst.
View noteDeep value opportunity trading at A$1.01 vs A$3.13 fair value. HHR network dominance with 10,496 units, pending Novomatic acquisition catalyst.
View noteAdairs trades at $2.59 vs $3.34 fair value (29% upside), with transformation under new CEO showing early momentum (22.6% Q1 sales growth) though Focus challenges and technology execution create 53% combined failure probability requiring disciplined risk management.
View noteTrading at $4.48 vs fair value $6.48, ABB shows 44.6% upside with 8.4% NBN market share, 11.6% EBITDA margins, and diversified revenue streams.
View noteLife360 rated Attractive with $92.34 fair value. Category-leading family safety platform with 65% market share, 32% revenue CAGR, expanding internationally with advertising monetisation upside.
View noteHOLD rating with $2.85 fair value vs $2.655 current price. 6.2% yield, 99.9% occupancy, but EV transition risks limit growth.
View noteWHC trades at $6.77 versus $12.19 fair value (80% upside). Australia's #3 coal producer with strong FCF generation and integration synergies.
View noteFair value $4.47 vs current $2.53 (77% upside). Australia's #5 gold producer with 7Mtpa processing capacity, 13% production CAGR, trading 22% below peers despite superior growth.
View noteViva Leisure trades at $1.345 versus $8.29 fair value (517% upside). Technology platform growing 127.7% with 92% recurring revenue model.
View noteMarket-leading general insurer with 32.1% share, fair value $16.13, 4.8% yield, strong capital position offset by margin compression risks
View noteDeep value opportunity trading at $0.14 vs $0.92 fair value (557% upside). Strong financial health, improving trajectory, medium risk profile.
View noteRio Tinto analysis reveals 28% upside potential through operational excellence and energy transition positioning, with fair value $107.22 USD versus current market pricing.
View notePro Medicus fair value $16.11 with 80% EBITDA margins facing inevitable compression as competitive response intensifies over 3-5 years.
View note